ERBB2 and cancer: Even though many of the available mAbs currently used in cancer therapy, such as rituximab (anti-CD20), trastuzumab (anti-HER2/neu), and cetuximab (anti-EGFR), have all been demonstrated to possess intrinsic antitumoral activity in vitro [6], significant cytotoxicity or cytostaticity is achieved at high concentrations.